Fc receptors for IgG (FcγR) link innate and adaptive immunity by their ability to mediate eff ector cell interactions with antigen-antibody (Ab) complexes and Ab-coated target cells (1, 2) . Mouse eff ector cells express four different FcγR classes: FcγRI (CD64), FcγRIIB (CD32), FcγRIII (CD16), and the recently described FcγRIV (also termed FcRL3 and CD16-2; references 3-5). FcγRIV is expressed by myeloid cells and shares 63% amino acid sequence identity with FcγRIII (CD16) in humans (3) (4) (5) . FcγRI, FcγRIII, and FcγRIV are hetero-oligomeric receptors in which the respective ligand-binding α chains generate stimulatory signals through ITAM sequences found within a shared common γ chain subunit (Fc receptor common γ chain [FcRγ] ) that is required for FcγR assembly. FcRγ chain ITAM sequences are essential to initiate or augment eff ector cell responses such as Ab-dependent cellular cytotoxicity (ADCC) and phagocytosis (1, 2). High-affi nity FcγRI preferentially binds monomeric IgG2a, whereas FcγRIII binds with low affi nity to IgG2a/IgG1/IgG2b, and FcγRIV binds with intermediate affi nity to IgG2a and IgG2b in vitro (1) . In contrast to stimulatory FcγRs, FcγRIIB contains ITIM sequences that inhibit eff ector cell responses. Coexpression of both activation and inhibitory FcγRs on macrophages, neutrophils, and mast cells appropriately balances protective and pathogenic innate eff ector responses after IgG immune complex engagement (6) . Imbalances between stimulatory and inhibitory FcγR functions can also contribute to autoimmunity in humans and mice (7) .
Chimeric or radiolabeled mAb therapies directed against CD20 expressed by mature B lymphocytes represent an eff ective treatment for non-Hodgkin's lymphoma (8) (9) (10) (11) (12) and may treat rheumatoid arthritis, idiopathic thrombocytopenic purpura, hemolytic anemia, and other immune-mediated diseases (13, 14) . Mouse anti-mouse CD20 mAbs (15) have provided a preclinical model for CD20 mAb immunotherapy amenable to mechanistic studies and genetic manipulation. In this model, CD20 mAbs engage the innate mononuclear phagocytic network and deplete blood and tissue B cells through FcγR-dependent and complement-independent mechanisms (16, 17) . These anti-mouse CD20 mAbs thereby provide effective tools for understanding how innate eff ector mechanisms function in vivo. B cell depletion is CD20 mAb isotype specifi c, with IgG2a/c mAbs exhibiting the greatest potency (16) . An IgG2c CD20 mAb eff ectively depletes B cells in both FcγRI −/− and FcγRIII −/− mice, but is not eff ective in FcRγ −/− mice (16) . The recently identifi ed functional characteristics of FcγRIV may explain the FcγR dependence but FcγRI and FcγRIII independence of this IgG2c CD20 mAb in vivo. These Ab isotype-specifi c eff ects are clinically important because the antitumor eff ect of CD20 mAbs in humans depends in part on FcγR-dependent immune activation (18) , and a chimeric CD20 mAb of an isotype diff erent than that used clinically does not deplete normal B cells in nonhuman primates (19) . Moreover, human FcγRIIa and FcγRIIIa polymorphisms correlate with the effi ciency of B cell and tumor depletion during CD20 mAb therapy in lupus and lymphoma patients (20) (21) (22) . Thus, a molecular understanding of the diff erent roles of each FcγR during B cell depletion is essential for mechanism-based predictions of biological outcomes for mAb-based immunotherapies.
To identify molecular mechanisms of innate eff ector cell function in vivo, B cell depletion was assessed in mice with FcγRI, FcγRIIB, FcγRIII, FcγRIV, or FcRγ blockade or defi ciency using IgG1, IgG2a/c, and IgG2b isotype mAbs that bind mouse CD20. We show that IgG1 CD20 mAb-induced B cell depletion predominantly, if not exclusively, required FcγRIII expression, whereas IgG2a/c and IgG2b CD20 mAb-induced B cell depletion was primarily performed through FcγRIV with potential FcγRI interactions. In contrast, FcγRIIB expression inhibited CD20 mAb-induced B cell depletion in vivo. These fi ndings provide new insight into the therapeutic as well as potentially pathogenic innate eff ector mechanisms that can mediate ADCC in vivo. 
RESULTS

Isotype-specifi c CD20 mAb depletion of B cells in vivo
Six CD20 mAbs representative of each IgG isotype eff ective for B cell depletion, IgG1 (MB20-1 and MB20-14), IgG2a (MB20-16), IgG2c (MB20-11), and IgG2b (MB20-7 and MB20-18), were assessed for their ability to deplete blood and tissue B cells in vivo in a dose-dependent manner 7 d after mAb administration. Although the MB20-18 mAb reacted with B cells at the highest density among CD20 mAbs, each individual CD20 mAb reacted similarly with blood, spleen, and lymph node B220 + cells from wild-type, FcRγ −/− , FcγRI −/− , FcγRIIB −/− , and FcγRIII −/− mice ( Fig. 1 and not depicted) .
When mAb depletion of tissue B cells in wild-type mice was assessed over a range of mAb concentrations (1-250 μg/ mouse), a hierarchy of depletion effi ciencies for bone marrow, blood, spleen, and lymph node B cells was observed with MB20-11 (IgG2c) displaying the greatest activity (Fig. 2 A  and Table I ). Similar, if not identical, results were obtained using the IgG2a (MB20-16) mAb (not depicted), suggesting that IgG2a/c mAbs were similar in their abilities to bind FcγR. The IgG1 (MB20-1 and MB20-14) and IgG2b (MB20-18) mAbs depleted B cells similarly when used at low mAb concentrations, although the IgG1 mAbs depleted signifi cantly more spleen B cells than the MB20-18 mAb when used at 250-μg doses (Fig. 2 A, Table I , and not depicted) as described previously (16) . Each of the mAbs (MB20-11, MB20-16, MB20-1, MB20-14, and MB20-18) was saturating at >25-μg doses, which represented the maximal levels of depletion possible, even with higher mAb doses over a 7-d treatment period ( Fig. 2 A and Table I ). The MB20-7 mAb did not deplete B cells effi ciently at any dose (not depicted). The high reactivity of MB20-18 with B cells (Fig. 1 ) may explain why this mAb depleted 84-94% of wild-type spleen B cells when used value) relative to control mAb-treated littermates (250 μg; two or more mice per value). Signifi cant differences between sample means of mice treated with MB20-1 and MB20-11 mAbs (*, P < 0.05; **, P < 0.01) or MB20-1 and MB20-18 mAbs ( †, P < 0.05; † †, P < 0.01) are indicated. (B) Comparison of B cell depletion for each mAb isotype in FcRγ −/− , FcγRI −/− , and FcγRIII −/− mice as shown in A. Signifi cant differences between sample means of wild-type mice and each mutant strain are indicated: †, P < 0.05; † †, P < 0.01. a B cell subsets were: bone marrow pro-/pre-B (IgM − B220 lo ), immature B (IgM + B220 lo ), and mature B (IgM + B220 hi ); spleen mature (CD24 + CD21 + B220 + ), T1 (CD24 hi CD21 − B220 + ), and T2 (CD24 hi CD21 + B220 + ); and peritoneal B-1a (CD5 + CD11b + IgM hi B220 lo ), B-1b (CD5 − CD11b + IgM hi B220 lo ), and B2 (CD5 − IgM lo B220 hi ). LN, lymph node. b Pooled values indicate the percentages of B cells in CD20 mAb-treated mice (50-250 μg; IgG1 MB20-1, IgG2c MB20-11, and IgG2b MB20-18) relative to control mAb-treated littermates (50-250 μg; n ≥ 4 per value). Signifi cant differences between mean B cell numbers in CD20 mAb-treated mice compared with control mAb-treated littermates are indicated: c P < 0.05 and f p < 0.01. Signifi cant differences between mean percentages of B cells in each mutant mouse strain after CD20 mAb treatment relative to percentages obtained in wild type mice are indicated: d P < 0.05 and e P < 0.01.
at 250 μg/mouse (Table I) , whereas the MB20-7 and two other IgG2b CD20 mAbs only depleted 3-36% of B cells (16) . The IgG1, IgG2a/c, and IgG2b CD20 mAbs signifi cantly depleted mature bone marrow and circulating B cells, with T1, T2, and mature B cells depleted from the spleen and lymph nodes, whereas peritoneal B cells were only signifi cantly depleted using IgG2a/c CD20 mAbs in wild-type mice (Table I and not depicted). Isotype-matched control mAbs had no measurable eff ects on B cell numbers (not depicted). Two different IgG3 CD20 mAbs (MB20-3 and MB20-13) failed to ARTICLE deplete signifi cant numbers of tissue B cells when used at any concentration, as described previously (16 
Roles for activating Fc Rs in B cell depletion
The roles of individual FcγRs in B cell depletion by CD20 mAbs were assessed by directly comparing B cell depletion in mice defi cient in FcRγ, FcγRI, or FcγRIII. IgG1, IgG2a/c, and IgG2b CD20 mAbs each required FcRγ expression for the majority of bone marrow, blood, and tissue B cell depletion ( Fig. 2 B, Table I , and not depicted), as described previously (16) . Uniquely, FcγRIII expression was required for MB20-1 (IgG1) mAb treatment but had no eff ect on IgG2a/c or IgG2b CD20 mAb-induced B cell depletion. Two independent FcγRIII −/− mouse lines (23, 24) generated identical results (not depicted). In contrast, FcγRI defi ciency had much less dramatic eff ects on CD20 mAb-induced B cell depletion. Thus, IgG1 CD20 mAbs preferentially, if not exclusively, used FcγRIII for B cell depletion in vivo. The role of the newly identifi ed FcγRIV molecule in B cell depletion by IgG2b (100 μg MB20-18) and IgG2c (25 μg MB20-11) CD20 mAbs was assessed using FcγRI −/− / FcγRIII −/− mice, where only FcγRIV is expressed. At these doses, both the IgG2b and IgG2c CD20 mAbs depleted signifi cant numbers of blood and spleen B cells in both FcγRI −/− /FcγRIII −/− and wild-type mice (Fig. 3 A) . Combined FcγRI/FcγRIII defi ciencies inhibited IgG2b CD20 mAb-induced B cell depletion when compared with wild-type mice, suggesting that FcγRI and/or FcγRIII may contribute to IgG2b/c CD20 mAb depletion in addition to FcγRIV. Regardless, FcγRIV mediated eff ective IgG2b and IgG2c CD20 mAb-induced B cell depletion in the absence of both FcγRI and FcγRIII expression. The role of FcγRIV in B cell depletion by IgG2b CD20 mAbs was further verifi ed in wild-type mice using the recently described FcγRIV function-blocking mAb, 9E9 (5). The MB20-18 (IgG2b) mAb at 100 μg depleted between 50 and 90% of blood and tissue B cells, but this was signifi cantly attenuated or eliminated when FcγRIV function was blocked using the 9E9 mAb (Fig. 3 B) . These results suggest that FcγRIV preferentially mediates IgG2b CD20 mAb-induced B cell depletion.
In wild-type mice, the IgG2c MB20-11 mAb at 2.5 μg/ mouse depleted most circulating (>95%) B cells by day 7 and signifi cantly reduced spleen and lymph node B cell numbers (Fig. 3 C) . Blocking FcγRIV activity with the 9E9 mAb in wild-type mice treated with low-dose MB20-11 mAb inhibited lymph node B cell depletion but did not signifi cantly reduce blood and spleen B cell depletion. However, blocking FcγRIV function in FcγRI −/− mice signifi cantly aff ected the ability of IgG2c CD20 mAbs to deplete B cells in vivo. Specifi cally, 60% of circulating B cells were depleted in FcγRI −/− mice treated with low-dose MB20-11 mAb (2.5 μg), whereas B cell depletion was not observed when FcγRIV function was also blocked. Circulating, splenic, and lymph node B cells in FcγRI −/− mice were also signifi cantly depleted by MB20-11 mAb at a 25-μg dose, but B cell depletion was signifi cantly reduced when FcγRIV function was also blocked. Thus, FcγRIV contributed substantially to IgG2c CD20 mAbinduced B cell depletion, but FcγRI expression may also facilitate B cell depletion by the MB20-11 mAb, particularly when CD20 mAb doses are limiting.
Role for Fc RIIB in B cell depletion As an inhibitory receptor expressed by monocytes and B cells, FcγRIIB defi ciency could aff ect B cell depletion. Therefore, FcγRIIB −/− mice were treated with IgG1, IgG2a/c, and IgG2b CD20 mAbs over a range of concentrations. Splenic and lymph node B cell depletion by IgG1 CD20 mAb treatment was signifi cantly augmented in FcγRIIB −/− mice when used at 50-100-μg doses (Fig. 4 and not depicted). Lymph node B cell depletion by IgG2a/c and IgG2b CD20 mAbs was also signifi cantly enhanced by FcγRIIB defi ciency (Fig. 4 and not depicted) . The MB20-1 (IgG1) and MB20-18 (IgG2b) mAbs depleted >90% of 
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lymph node B cells when used at ≥25-μg doses in FcγRIIB −/− mice, whereas these mAbs maximally depleted 70-80% of B cells when used at higher concentrations in wild-type littermates. The MB20-11 IgG2c mAb depleted 90% of lymph node B cells at 10-fold lower mAb concentrations in FcγRIIB −/− mice. As a result, lymph node B cell depletion in FcγRIIB −/− mice was as effi cient as spleen B cell depletion in CD20 mAb-treated wild-type mice. FcγRIIB defi ciency did not signifi cantly enhance the degree of bone marrow or blood B cell clearance. Within the peritoneal cavity, FcγRIIB defi ciency did not enhance the degree of peritoneal B-1a and B-1b cell clearance after CD20 mAb treatments but did facilitate IgG1 CD20 mAb-induced depletion of conventional B2 cells (Table I) . Thus, expression (Fig. 5 A) . It was therefore assessed whether augmented B cell depletion in FcγRIIB −/− mice resulted from a change in B cell or monocyte FcγRIIB expression. FcγRIIB −/− splenocytes and control splenocytes from wild-type mice were diff erentially labeled with CFSE, mixed together in equal proportions, and adoptively transferred into recipient mice 1 d before CD20 mAb treatment. 1 d after CD20 mAb treatment, the relative frequencies of CFSE-labeled B220 + and B220 − lymphocytes in the blood, spleen, and lymph nodes were quantifi ed by fl ow cytometry (Fig. 5 B) . The relative frequency of wildtype B220 + lymphocytes in the blood, spleen, and lymph nodes was more signifi cantly reduced in MB20-11 CD20 mAb-treated mice when compared with the frequency of FcγRIIB −/− B220 + lymphocytes. Control mAb treatment did not aff ect the relative ratios of B220 + FcγRIIB −/− and B220 + wild-type lymphocytes in these adoptive transfer experiments. Likewise, CD20 mAb treatment did not aff ect the relative ratios of B220 − FcγRIIB −/− and B220 − wild-type lymphocytes. Thus, FcγRIIB defi ciency reduced the relative rate of B cell depletion compared with wild-type B cells, although FcγRIIB −/− B cells were eff ectively depleted after 7 d of CD20 mAb treatment (Table I) .
Role for Fc Rs in B cell subset depletion
Subtle eff ects of FcγR defi ciencies on B cell subset depletion were also observed (Table I) . For example, the number of pro-/pre-B cells present in bone marrow after IgG1 mAb treatment was signifi cantly increased in FcγRI −/− mice. Similar eff ects on immature bone marrow B cells in FcγRI −/− mice were observed after IgG1 and IgG2b mAb treatments. MB20-11 mAb treatment also increased spleen B cell numbers in FcRγ −/− mice compared with control mAb-treated littermates, predominantly due to increased numbers of immature B cells (not depicted). Thus, alterations in FcγR expression signifi cantly aff ected the dynamics of B cell subset depletion after CD20 mAb treatment.
DISCUSSION
The extent of B cell depletion induced by CD20 mAbs correlated closely with IgG isotype, with IgG2a/c mAbs being the most eff ective and IgG3 mAbs having modest eff ects in vivo ( Fig. 1 and Table I ; reference 16). Although our previous studies suggested reciprocal roles for FcγRI or FcγRIII in CD20 mAb-induced depletion of B cells (16) , the current studies demonstrate that diff erential FcγR utilization explains diff erences in eff ectiveness between CD20 mAb isotypes. IgG1 CD20 mAb-induced B cell depletion was predominantly, if not exclusively, performed through low-affi nity FcγRIII ( Fig. 2 and Table I ). Preferential IgG1 interactions with FcγRIII for phagocytosis of IgG1-coated erythrocytes or immune complexes, and in animal models of experimental autoimmune hemolytic anemia and passive cutaneous anaphylaxis, have been demonstrated previously (25, 26) . In contrast, IgG2b and IgG2a/c CD20 mAb-induced B cell depletion was primarily performed through intermediate affi nity FcγRIV, although high-affi nity FcγRI interactions may also contribute to this process (Figs. 2 and 3) . Importantly, FcγRIV mediated eff ective B cell deletion by both IgG2a/c and IgG2b CD20 mAbs in the absence of both FcγRI and FcγRIII (Fig. 3 A) . Because simultaneous blockade of FcγRIV function and FcγRI expression prevented B cell depletion by IgG2b and IgG2a/c CD20 mAbs, FcγRIII may have minimal interactions with these mAb isotypes. Although mouse IgG3 is reported to bind FcγRI (27), IgG3 CD20 mAbs had little eff ect in vivo (16) . Thus, monocyte expression of either FcγRIV or FcγRIII is suffi cient for B cell depletion when mAbs of the correct isotypes are considered. These fi ndings explain why IgG2a/c CD20 mAb therapy was eff ective in both FcγRI −/− and FcγRIII −/− mice, but not in FcRγ −/− mice ( Fig. 2 B and Table I ; reference 16). Thereby, each IgG isotype demonstrated preferential specifi city for different stimulatory FcγRs. The importance of mAb isotype in immunotherapy has long been appreciated, particularly for mouse IgG2a mAbs (28) (29) (30) (31) (32) . Like IgG2a/c CD20 mAbs for B cell depletion ( Fig. 2 A and not depicted) , IgG2a anti-erythrocyte mAbs induce more severe FcγR-dependent hemolytic anemia than IgG2b mAbs (33) . However, because FcγRIV binds IgG2a and IgG2b mAbs with similar affi nities in vitro (5), it was surprising that IgG2a/c CD20 mAbs depleted B cells at least 10-fold better than the IgG2b MB20-18 CD20 mAb in vivo ( Fig. 1; reference 16) . Moreover, the MB20-18 mAb primarily used in the current studies is the most potent of four IgG2b CD20 mAbs assessed for B cell depletion (16) . It is therefore possible that engagement of both FcγRIV and FcγRI by IgG2a/c CD20 mAbs explains their higher potency in vivo (Fig. 3 A) . High-affi nity FcγRI may participate in some IgG2a-mediated eff ects in certain experimental model systems, although FcγRI may play a minor role in vivo because administered mAbs must compete with intrinsic circulating Abs for high-affi nity FcγRI interactions (34) . Determining the precise contribution of FcγRI to IgG2a/b/c CD20 mAb eff ectiveness in vivo will require the generation and characterization of FcγRIV-defi cient mice. Alternatively, mAb isotype-specifi c structural features may explain the potency of IgG2a isotype CD20 mAbs in vivo. For example, IgG2a/c and IgG2b CD20 mAbs may bind cell surface CD20 diff erently or have diff erent eff ects on target antigen/Ab densities during CD20 mAb-induced ADCC, or allow the effi cient clustering of CD20 on the surface of B cells. IgG2a/c isotype switching may also select for CD20 mAbs with high intrinsic potencies, high mAb affi nities, or unique fi ne specifi cities for CD20. Regardless, the greater activity of IgG2a/c CD20 mAbs in vivo was not explained ARTICLE by unique eff ects on ADCC through FcγRIIB negative regulation (Fig. 4) . CD20 mAb-induced B cell depletion was reduced by monocyte expression of FcγRIIB in vivo, with FcγRIIB defi ciency also revealing tissue-specifi c eff ects on B cells (Fig.  4 and Table I ). FcγRIIB defi ciency signifi cantly enhanced lymph node B cell depletion by IgG1, IgG2c, and IgG2b CD20 mAbs, whereas FcγRIIB defi ciency only enhanced IgG1 CD20 mAb-induced spleen B cell depletion when used at higher mAb doses. Lymph node B cell depletion was less effi cient than spleen B cell depletion at equivalent CD20 mAb doses, but lymph node and spleen B cell depletion were similar in the absence of FcγRIIB expression. Likewise, FcγRIIB defi ciency did not signifi cantly enhance B-1a or B-1b cell depletion from the peritoneal cavity (Table I) , populations of B cells that are more resistant to CD20 mAbinduced depletion than peritoneal B2 cells (17) . Therefore, circumventing the negative regulatory role of FcγRIIB may be most advantageous during suboptimal mAb dosing or for B cell depletion within lymph nodes. Consistent with this, FcγRIIB deletion enhances the cytotoxicity of human Fc region-chimerized or -humanized mAbs targeting tumors in vivo, including rituximab targeting of human lymphoma cells in nude mice (18) . Surprisingly, however, FcγRIIB −/− B cells were also more resistant to CD20 mAb-induced depletion than wild-type B cells (Fig. 5) . FcγRIIB −/− B cell resistance to CD20 mAb treatment did not result from reduced CD20 expression (Fig. 1) , and peritoneal B-1a or B-1b cell resistance to CD20 mAb-induced depletion did not result from low FcγRIIB expression (Fig. 5 A) . Nonetheless, no signifi cant relationship has been found between FcγRIIB protein expression on diff use large B cell lymphomas and the prognosis of patients or their outcome after rituximab therapy (35) . Thus, circumventing monocyte inhibitory FcγRII function in vivo could result in more eff ective immunotherapies, but this may be infl uenced by tissue-specifi c factors including the localization of target B cells or ADCC eff ector cells.
Although tissue B cell clearance was FcRγ dependent, circulating B cell clearance was mediated through both FcRγ-dependent and -independent pathways. In the absence of FcRγ expression, 30-57% of circulating B cells were cleared by IgG1, IgG2a/c, and IgG2b CD20 mAbs on day 7 (Fig. 1, Table I , and not depicted). Similar results were obtained for mature bone marrow B cells, which include the recirculating B cell pool. Most IgG2b and IgG3 anti-mouse CD20 mAbs also deplete blood B cells but have modest, if any, eff ects on spleen B cells (16) . This demonstrates that blood and circulating bone marrow B cells share common properties that allow their clearance without operable ADCC. Rapid blood B cell depletion is also observed in patients after CD20 mAb infusions (36) (37) (38) (39) . However, the current results suggest that blood B cell clearance may not necessarily correlate with tissue B cell clearance. Consistent with this, human FcγRIIIa polymorphisms are not predictive of patient responses in chronic lymphocytic leukemia, which most commonly involves blood and marrow (40) . Thus, although FcγR-mediated ADCC remains a primary mechanism for B cell depletion in vivo, FcγR-independent pathways also infl uence the clearance of circulating B cells.
Collectively, these results indicate that the most important factors infl uencing CD20 mAb effi cacy in vivo are mAb isotype and capacity to interact with FcγRs. These results also further support previous fi ndings whereby Ab isotypes exhibit functional hierarchies in their relative abilities to engage diff erent FcγRs in vivo. The current immunotherapy studies also correlate with models of adaptive immunity where IgG2a Abs are most effi cient in providing optimal or substantial protection during bacterial, viral, and fungal infections (41) (42) (43) (44) (45) . Thus, the intricate innate eff ector pathways used for B cell depletion in the current studies may have been selected evolutionarily for potency. The current observations also corroborate studies in lupus and lymphoma patients showing that human FcγRIIa and FcγRIIIa polymorphisms correlate with the effi ciency of tumor and B cell depletion using a chimeric human IgG1 CD20 mAb (20) (21) (22) . That mouse FcγRIV is most structurally similar to human FcγRIII (3) (4) (5) further implicates the importance of this receptor in human B cell depletion after CD20 mAb treatment. Understanding whether human Ab isotypes exhibit a functional hierarchy in their relative abilities to engage diff erent FcγRs in vivo will be critical for better manipulating FcγR function during immunotherapy or ameliorating the consequences of pathogenic autoantibodies. The current studies also indicate that it may be important to consider disease-and tissuespecifi c targeting eff ects when manipulating FcγR expression or function for therapeutic benefi t. Because therapeutic andpathogenic Abs are likely to share many common pathways and FcγR-dependent processes, a further understanding of the molecular complexities of FcγR function and signaling in vivo are essential to fully harness the potent stimulatory and inhibitory functions of this receptor system in treating human disease.
MATERIALS AND METHODS
Abs and immunofl uorescence analysis. Mouse CD20-specifi c mouse mAbs were as described previously (15) . Hamster anti-mouse FcγRIV mAb, 9E9, was as described previously (5, 46) . Other mAbs included: B220 mAb RA3-6B2 (provided by R. Coff man, DNAX Corp., Palo Alto, CA); Thy1.2 mAb (Caltag); and CD1d (1B1), CD5 (53-7.3), CD11b (M1/70), CD16/32 (2.4G2), CD21 (7G6), and CD24 (M1/69) mAbs (BD Biosciences). Isotypespecifi c and anti-Ig or anti-IgM Abs were from SouthernBiotech.
Single-cell suspensions of bone marrow (bilateral femurs), spleen, and peripheral lymph node (paired axillary and inguinal) lymphocytes were generated by gentle dissection. To isolate peritoneal cavity leukocytes, 10 ml of cold (4°C) PBS was injected into the peritoneum of killed mice followed by gentle massage of the abdomen. Viable cells were counted using a hemocytometer, with relative lymphocyte percentages determined by fl ow cytometry analysis. Blood erythrocytes were lysed after immunofl uorescence staining using FACS Lysing Solution (BD Biosciences). Single-cell leukocyte suspensions were stained on ice using predetermined optimal concentrations of each Ab for 20-60 min and fi xed as described previously (47, 48) . Cells with the light scatter properties of lymphocytes were analyzed by two-to fourcolor immuno fl uorescence staining with FACScan or FACSCalibur fl ow cytometer analysis (Becton Dickinson). Background staining was determined using unreactive control mAbs (Caltag) with gates positioned to exclude ≥98% of the cells.
In some cases, B cell-enriched single-cell lymphocyte preparations were generated by incubating 2 × 10 8 splenocytes with 180 μl anti-Thy1.2 mAbcoated magnetic beads (Dynal) in 10 ml RPMI 1640 medium containing 5% FBS for 30 min at 4°C, followed by T cell removal using a magnet. B cell preparations were ≥93% B220 + as determined by immunofl uorescence staining with fl ow cytometry analysis. The B cell preparations were assessed for cell surface CD20 expression as described above, except 10 6 lymphocytes were incubated with each CD20 mAb at 10 μg/ml, washed, and incubated with PE-conjugated goat anti-mouse IgG1, IgG2a, or IgG2b isotype-specifi c secondary Ab for immunofl uorescence staining.
Mice. FcγRI −/− and FcγRIII −/− mice were as described previously (23) and crossed to generate FcγRI −/− /FcγRIII −/− mice. C57BL/6, FcγRIIB −/− (B6,129S-Fcgr2 tm1Rav ), and FcγRIII −/− (C57BL/6-Fcgr3 tm1Sjv ) mice were from The Jackson Laboratory. FcRγ-defi cient mice (FcRγ −/− , B6.129P2-Fcer1g tm1 ) were from Taconic Farms. All mice were housed in a specifi c pathogen-free barrier facility and fi rst used at 2-3 mo of age. All studies were approved by the Animal Care and Use Committee of Duke University.
Immunotherapy. Sterile anti-mouse CD20 and isotype control mAbs (1-250 μg) in 200 μl PBS were injected through lateral tail veins. Blood leukocyte numbers were quantifi ed by hemocytometer after red cell lysis, with blood and tissue B220 + B cell frequencies determined by immunofluorescence staining with flow cytometry analysis as described previously (16, 17) . Because equivalent results were obtained in mice treated with control IgG2a, IgG2b, or IgG1 mAbs, the results were pooled in some instances.
Adoptive transfer experiments. Unfractionated splenocytes from FcγRIIB −/− and wild-type mice were labeled with 4 and 0.4 μM Vybrant CFSE, respectively (Invitrogen), according to the manufacturer's instructions. The relative frequency of B220 + cells among CFSE-labeled splenocytes was determined by immunofl uorescence staining with fl ow cytometry analysis. Subsequently, equal numbers of CFSE-labeled B220 + FcγRIIB −/− and wild-type splenocytes (4 × 10 7 ) were injected i.v. into wild-type mice 1 d before i.v. injection of either MB20-11 or control mAbs. After 1 d, cells were harvested from each tissue and CFSE-labeled B220 + cells were analyzed by immunofl uorescence staining with fl ow cytometry analysis.
Statistical analysis. All data are shown as means ± SEM. The Student's t test was used to determine the signifi cance of diff erences between population means.
